Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder,The Lancet Neurology

当前位置： X-MOL 学术 › Lancet Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder
The Lancet Neurology ( IF 48.0 ) Pub Date : 2021-07-21 , DOI: 10.1016/s1474-4422(21)00176-9
Mitchell G Miglis ₁ , Charles H Adler ₂ , Elena Antelmi ₃ , Dario Arnaldi ₄ , Luca Baldelli ₅ , Bradley F Boeve ₆ , Matteo Cesari ₇ , Irene Dall'Antonia ₈ , Nico J Diederich ₉ , Kathrin Doppler ₁₀ , Petr Dušek ₈ , Raffaele Ferri ₁₁ , Jean-François Gagnon ₁₂ , Ziv Gan-Or ₁₃ , Wiebke Hermann ₁₄ , Birgit Högl ₇ , Michele T Hu ₁₅ , Alex Iranzo ₁₆ , Annette Janzen ₁₇ , Anastasia Kuzkina ₁₀ , Jee-Young Lee ₁₈ , Klaus L Leenders ₁₉ , Simon J G Lewis ₂₀ , Claudio Liguori ₂₁ , Jun Liu ₂₂ , Christine Lo ₁₅ , Kaylena A Ehgoetz Martens ₂₃ , Jiri Nepozitek ₈ , Giuseppe Plazzi ₂₄ , Federica Provini ₂₅ , Monica Puligheddu ₂₆ , Michal Rolinski ₂₇ , Jan Rusz ₂₈ , Ambra Stefani ₇ , Rebekah L S Summers ₂₉ , Dallah Yoo ₃₀ , Jennifer Zitser ₃₁ , Wolfgang H Oertel ₃₂

Affiliation

Department of Neurology and Neurological Sciences and Department of Psychiatry and Behavioral Science, Stanford University, Palo Alto, CA, USA.
Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ, USA.
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Clinical Neurology, DINOGMI, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Department of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, MN, USA.
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Department of Neurology and Center of Clinical Neuroscience, Charles University First Faculty of Medicine, Prague, Czech Republic.
Department of Neuroscience, Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg.
Department of Neurology, University of Würzburg, Würzburg, Germany.
Oasi Research Institute IRCCS, Troina, Italy.
Centre for Advanced Research in Sleep Medicine, Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal-Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada.
The Neuro-Montreal Neurological Institute-Hospital, Department of Neurology and Neurosurgery, and Department of Human Genetics, McGill University, Montreal, QC, Canada.
Department of Neurology, University of Rostock, Rostock, Germany; German Center for Neurodegenerative Diseases (DZNE), Research Site Rostock, Rostock, Germany.
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Sleep Disorders Center, Neurology Service, Hospital Clínic Barcelona, Universitat de Barcelona, Barcelona, Spain.
Department of Neurology and Section on Clinical Neuroscience, Philipps University Marburg, Marburg, Germany.
Department of Neurology, Seoul National University College of Medicine, Seoul, South Korea.
Department of Nuclear Medicine and Biomedical Imaging, University Medical Center Groningen, Groningen, Netherlands.
ForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia.
Sleep Medicine Center, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Kinesiology, Faculty of Applied Health Sciences, University of Waterloo, Waterloo, ON, Canada.
IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; UOC Clinica Neurologica Rete Metropolitana NEUROMET, Bellaria Hospital, Bologna, Italy.
Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Institute of Clinical Neurosciences, University of Bristol, Bristol, UK.
Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic.
Department of Neurology, University of Minnesota, Minneapolis, MN, USA.
Department of Neurology, Kyung Hee University Hospital, Seoul, South Korea.
Department of Neurology and Neurological Sciences, University of California, San Francisco, CA, USA; Department of Neurology, Tel Aviv Sourasky Medical Center, Affiliate of Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Neurology and Section on Clinical Neuroscience, Philipps University Marburg, Marburg, Germany; Institute for Neurogenomics, Helmholtz Center for Health and Environment, München-Neuherberg, Germany.

Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.

中文翻译：

孤立性快速眼动睡眠行为障碍转化为 α-突触核蛋白病的生物标志物

患有孤立性快速眼动睡眠行为障碍 (RBD) 的患者通常被认为处于涉及 α-突触核蛋白病理学的进行性神经退行性疾病的早期阶段，例如帕金森病、路易体痴呆或多系统萎缩。异常的 α-突触核蛋白沉积发生在中枢和周围神经系统的神经退行性过程的早期，并且可能在运动症状和认知能力下降之前几十年出现。这些发现为开发可靠的生物标志物提供了依据，这些生物标志物可以更好地预测转化为临床表现的 α-突触核蛋白病。此外，一旦疾病改善疗法可用，疾病进展的生物标志物对于监测治疗反应至关重要，

更新日期：2021-07-22

点击分享查看原文

点击收藏

阅读更多本刊最新论文

全部期刊列表>>